Bexson Biomedical, Inc., a research-stage company developing dosing and delivery solutions for mental health and pain management indications. Adds Sheldon Moberg as Senior VP, Drug Delivery will lead the development of Bexson’s drug delivery technologies, starting with a wearable infusion device for its BB106 therapy, in partnership with Italian drug containment solution and medical device manufacturer Stevanato Group.
Moberg said: “After many years in this field, I look forward to joining the Bexson team as they ramp up some truly groundbreaking device and delivery programs for pain management and other indications. I believe Bexson will be able to create viable solutions that not only have the potential for difficult to treat conditions, but that can also help in preventing them.”
Bexson’s lead indication is treating moderate to severe acute pain with its proprietary ketamine formulation, BB106, and a subcutaneous wearable device. In September 2020 Bexson signed an agreement with Stevanato Group to produce a customized version of the SG EZ-be Pod, a small, wearable, and programmable infusion device.
Jeffrey Becker, Co-Founder, and CSO, Bexson Biomedical, said: “Sheldon has a history of developing patient-centered devices that dramatically improve lives. With his help, the technology we’re developing with Stevanato Group has great potential for application beyond our non-opioid BB106 therapy for pain management. Sheldon’s expertise and innovations are allowing us to explore additional psychedelic and non-psychedelic therapies to help address treatment-resistant conditions.”
With the addition of Moberg, Bexson is expanding its drug delivery program to develop solutions for other drug therapies, where subcutaneous delivery and dosing control provide distinct advantages. Controlled delivery with a wearable pump can help solve limitations in dosing profile, bioavailability, pharmacokinetics, diversion risk, and GI side effects.